DDAVP® Tablet 0.1 mg 0.2 mg TO BE DISCONTINUED Minirin® Melt 60 mcg (to be launched soon) 120 mcg 240 mcg S4 MINIRIN® Melt 120 μg (sublingual tablet) Each unit contains 120 μg desmopressin acetate (120 μg free base) Registration No.: A42/18.2/0346. S4 MINIRIN® Melt 240 μg (sublingual tablet) Each unit contains 240 μg desmopressin acetate (240 μg free base) Registration No.: A42/18.2/0347. S4 MINIRIN® Melt 60 μg (sublingual tablet) Each unit contains 60 μg desmopressin acetate (60 μg free base) Registration No.: A42/18.2/0345. S4 DDAVP® Tablet 0,1 mg. Each tablet contains desmopressin acetate 0,1 mg. Reg No.: A29/18.2/0429. S4 DDAVP® Tablet 0,2 mg. Each tablet contains desmopressin acetate 0,2 mg. Reg No.: A34/18.2/0402. NAME AND BUSINESS ADDRESS OF THE HOLDER OF THE CERTIFICATE OF REGISTRATION: FERRING (Pty.) Ltd. Route 21 Corporate Park, 6 Regency Drive, Irene Ext 30. Pretoria, South Africa. Tel: +27 12 345 6358 Fax: +27 12 345 1156. www.ferring.co.za. DDAVP, MINIRIN MELT, FERRING, and the FERRING logo are registered trademarks of Ferring B.V. For full prescribing information please refer to the package insert approved by the medicines regulatory authority. For medical enquiries or to report any adverse events, please send an email to safety.mailbox3@ferring.com. https://bit.ly/3hUP4km. ZA-MN-2300005 Effective date: July 2023. Switch to Minirin® Melt - The PREFERRED FORMULATION for the MAJORITY OF PATIENTS1,2 IMPROVED RESPONSE and COMPLIANCE compared to tablet2 Can be taken without water3 SIMILARLY PRICED to DDAVP tablets®4 Minirin® Melt is indicated for: 1. Management of Central Diabetes Insipidus3 2. The symptomatic short term (4-8 weeks) treatment of primary nocturnal enuresis in children older than 5 years who have normal ability to concentrate urine3 References: 1. Lottmann H, et al. A randomised comparison of oral desmopressin lyophilisate (MELT) and tablet formulations in children and adolescents with primary nocturnal enuresis Journal compilation. Int J Clin Pract. September 2007,61(9):1454-1460. 2. Juul KV, et al. Desmopressin melt improves response and compliance compared with tablet in treatment of primary monosymptomatic nocturnal enuresis. Eur J Pediatr. 2013;172:1235-1242. 3. MINIRIN® Melt Registered Package Insert, dated 06 March 2014. 4. Database of Medicine Prices 14 June 2023. Switch from DDAVP® tablet to Minirin® Melt TODAY How to switch from tablets to Melt formulation:2 DDAVP® 0.2 mg is equal to Minirin® Melt 120 mcg 2x DDAVP® 0.2 mg is equal to Minirin® Melt 240 mcg
RkJQdWJsaXNoZXIy NTIyOTQ=